Ege University Hospital

Izmir 35100

0 studies enrolling now · 7 studies all time

What they study most

Anemia, B-Cell Malignancies, Beta-Thalassemia, Chronic Cough, Fabry Disease, IPF, Myelofibrosis, Persistent Cough in IPF, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Primary Myelofibrosis, Transfusional Iron Overload

Studies at this site

• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections — Running, not enrolling
• A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy. — Completed
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload — Stopped early
• A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF — Stopped early